[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes
Sumber 柳叶刀 LancetBaru sahaja
Ringkasan kandungan
This item is a English-language original; headline and summary shown as published.
Cardiovascular outcomes trials with GLP-1 receptor agonists, which to date have largely comprised peptide analogues of the incretin hormone GLP-1, have evolved…
Laman ini hanya menyediakan indeks tajuk dan ringkasan, kandungan penuh dan hak cipta adalah milik pihak penerbit asal, sila klik pautan asal untuk membaca.
Pergi ke artikel asal- Saluran berkaitan
- Kesihatan
- Kawasan berkaitan
- United Kingdom
- Bahasa teks asal
- English
- Nombor entri
- health-1d503d72
Comments 0 comments
No comments yet. Be the first.